Literature DB >> 12091679

Single-bolus technique for spiral CT of laryngopharyngeal squamous cell carcinoma: comparison of different contrast material volumes, flow rates, and start delays.

Marc Keberle1, Alexander Tschammler, Dietbert Hahn.   

Abstract

PURPOSE: To evaluate different contrast material volumes, flow rates, and start delays for contrast material enhancement of neck structures and squamous cell carcinoma to determine the most effective examination protocol.
MATERIALS AND METHODS: Seventy patients with squamous cell carcinoma were prospectively randomized into four groups for examination with different protocols (125 mL of contrast material administered at a flow rate of 2.5 mL/sec, 100 mL at 2.0 mL/sec, 90 mL at 1.5 mL/sec, or 70 mL at 1.0 mL/sec). Dynamic series were performed on the tumors and relevant anatomic structures to obtain time-attenuation curves. The protocols were compared (analysis of variance and Tukey-Kramer tests) with regard to time and level of maximum tumor enhancement and carotid arterial enhancement of more than 150 HU. One selected protocol was tested in 30 additional routine examinations with start delays of 40 seconds (for laryngeal and/or hypopharyngeal tumors, 3-mm collimation) and 45 seconds (for oropharyngeal tumors, 5-mm collimation).
RESULTS: Except for the 70-mL bolus administered at 1.0 mL/sec, the other protocols performed similarly well, yielding comparable maximum tumor enhancement at 52 seconds and later. In spite of a smaller volume of 90 mL, due to the prolonged flow time at 1.5 mL/sec, carotid arterial enhancement of more than 150 HU was prolonged (when compared with that in 100- or 125-mL protocols). As a result of these circumstances, injection of 90 mL at 1.5 mL/sec was considered more effective, providing no significant differences in tumor (P =.39) or carotid arterial (P =.52) enhancement between routine examinations and dynamic series.
CONCLUSION: A single bolus of 90 mL administered at 1.5 mL/sec appears to be the most desirable protocol for contrast enhancement.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091679     DOI: 10.1148/radiol.2241010894

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  6 in total

1.  Multi-detector row CT of the head and neck: comparison of different volumes of contrast material with and without a saline chaser.

Authors:  Dae Young Yoon; Su Yeon You; Chul Soon Choi; Suk Ki Chang; Eun Joo Yun; Young Lan Seo; Sang Joon Park; Yu-Jin Lee; Jeung Hee Moon; Young-Soo Rho; Jin-Hwan Kim
Journal:  Neuroradiology       Date:  2006-09-15       Impact factor: 2.804

2.  Computed tomography angiography versus digital subtraction angiography in vascular mapping for planning of microsurgical reconstruction of the mandible.

Authors:  Michael Lell; Bernd F Tomandl; Katharina Anders; Ulrich Baum; Emeka Nkenke
Journal:  Eur Radiol       Date:  2005-04-27       Impact factor: 5.315

3.  Enhancement of anatomical structures and detection of metastatic cervical lymph nodes: comparison of two different contrast material doses.

Authors:  Haruo Watanabe; Masayuki Kanematsu; Hiroki Kato; Toshihisa Kojima; Toshiharu Miyoshi; Satoshi Goshima; Hiroshi Kondo; Hiroshi Kawada; Yoshifumi Noda; Noriyuki Moriyama
Journal:  Jpn J Radiol       Date:  2012-09-25       Impact factor: 2.374

4.  Comparison of different patient positioning strategies to minimize shoulder girdle artifacts in head and neck CT.

Authors:  Stefan Wirth; Thomas Meindl; Marcus Treitl; Klaus-Jürgen Pfeifer; Maximilian Reiser
Journal:  Eur Radiol       Date:  2006-03-17       Impact factor: 5.315

5.  CT determination of lymphocytic infiltration around head and neck squamous cell carcinomas may be a predictor of lymph node metastases.

Authors:  Marc Keberle; Philipp Ströbel; Alexander Marx; Dietbert Hahn; Florian Hoppe
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-06-26       Impact factor: 2.503

Review 6.  Staging of laryngeal and hypopharyngeal cancer: value of imaging studies.

Authors:  Robert Hermans
Journal:  Eur Radiol       Date:  2006-05-30       Impact factor: 7.034

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.